Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DTIL 
Precision BioSciences Inc (DTIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: DTIL (1-star) is a SELL. SELL since 4 days. Profits (-23.44%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.24% | Avg. Invested days 17 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.00M USD | Price to earnings Ratio 4.54 | 1Y Target Price 33.6 |
Price to earnings Ratio 4.54 | 1Y Target Price 33.6 | ||
Volume (30-day avg) 147146 | Beta 1.59 | 52 Weeks Range 3.61 - 15.97 | Updated Date 03/31/2025 |
52 Weeks Range 3.61 - 15.97 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-25 | When Before Market | Estimate -2.945 | Actual -2.136 |
Profitability
Profit Margin 10.43% | Operating Margin (TTM) -3894.36% |
Management Effectiveness
Return on Assets (TTM) -11.04% | Return on Equity (TTM) 19.05% |
Valuation
Trailing PE 4.54 | Forward PE 2.11 | Enterprise Value -6687467 | Price to Sales(TTM) 0.73 |
Enterprise Value -6687467 | Price to Sales(TTM) 0.73 | ||
Enterprise Value to Revenue 0.18 | Enterprise Value to EBITDA -0.27 | Shares Outstanding 10481900 | Shares Floating 8756605 |
Shares Outstanding 10481900 | Shares Floating 8756605 | ||
Percent Insiders 18.11 | Percent Institutions 38.01 |
Analyst Ratings
Rating 4.6 | Target Price 33.6 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Precision BioSciences Inc
Company Overview
History and Background
Precision BioSciences Inc. was founded in 2006. It is a genome editing company dedicated to improving life through its ARCUS platform. They've focused on developing allogeneic CAR T cell therapies and in vivo gene editing therapies.
Core Business Areas
- Allogeneic CAR T Cell Therapy: Developing off-the-shelf CAR T cell therapies using ARCUS genome editing for cancer treatment.
- In Vivo Gene Editing: Developing therapies that use ARCUS to directly edit genes within the patient's body.
- ARCUS Platform Licensing: Out-licensing their ARCUS gene editing technology to other companies for their therapeutic applications.
Leadership and Structure
Derek Jantz is the co-founder and CSO. Michael Amoroso is the CEO. The company operates with a functional structure aligned with research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- PBCAR0191: An allogeneic CAR T cell therapy targeting CD19 for B-cell malignancies. Currently in clinical trials. Market share is difficult to determine due to developmental stage. Competitors include companies developing allogeneic CAR-T therapies such as Allogene Therapeutics (ALLO) and CRISPR Therapeutics (CRSP).
- In Vivo Gene Editing Programs: Development of gene editing therapies for various diseases including Hepatitis B. Market share is currently minimal due to pre-commercial status. Competitors include Editas Medicine (EDIT) and Intellia Therapeutics (NTLA).
Market Dynamics
Industry Overview
The gene editing and cell therapy industries are rapidly growing, driven by advances in technology and increasing clinical success. High investment and regulatory scrutiny are characteristic.
Positioning
Precision BioSciences is positioned as a leader in ARCUS-based genome editing, offering a differentiated approach compared to CRISPR-based technologies. They aim to provide safer and more precise editing capabilities.
Total Addressable Market (TAM)
The total addressable market for gene editing and cell therapy is projected to reach tens of billions of dollars. Precision BioSciences is targeting segments within oncology and genetic diseases, positioning them to capture a portion of this expansive market.
Upturn SWOT Analysis
Strengths
- Proprietary ARCUS gene editing platform
- Potential for high precision and specificity
- Experienced management team
- Advancing clinical pipeline
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Reliance on clinical trial success
- Competition from established gene editing technologies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of ARCUS platform to new therapeutic areas
- Positive clinical trial results
- Increasing investor interest in gene editing
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene editing technologies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- ALLO
- CRSP
- EDIT
- NTLA
Competitive Landscape
Precision BioSciences' ARCUS platform offers a different approach to gene editing compared to CRISPR, potentially offering advantages in specificity and safety. However, CRISPR-based therapies have a head start in terms of clinical development and market acceptance.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by expansion of research and development programs and securing partnerships. Revenue is dependent on milestone payments.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates vary widely depending on the perceived likelihood of success of their pipeline.
Recent Initiatives: Focusing on the development of next-generation CAR T cell therapies and in vivo gene editing programs.
Summary
Precision BioSciences is a clinical-stage biotechnology company with a proprietary gene editing platform (ARCUS). The company's success heavily depends on the positive outcomes of its clinical trials. Competition is fierce in this space, with multiple players. Precision Biosciences needs to continue securing partnerships to fund its ongoing R&D costs.
Similar Companies
- ALLO
- CRSP
- EDIT
- NTLA
- BMY
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Analyst reports
- Press releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and subject to change. Financial data is dynamic, refer to most recent reports for details.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precision BioSciences Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2019-03-28 | President, CEO & Director Mr. Michael Amoroso | ||
Sector Healthcare | Industry Biotechnology | Full time employees 108 | |
Full time employees 108 | |||
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.